Delving into the Latest Updates on CD19/CD20 dual-target CAR-T (Shenzhen Universtiy) with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms-

Target

CD19 x CD20

Action

inhibitors

Mechanism

CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

B-cell lymphoma recurrentB-cell lymphoma refractory

Inactive Indication

Carney ComplexRefractory Lymphoma

Originator Organization

Shenzhen University General Hospital

Active Organization

Shenzhen University General Hospital

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

1. Study Title:
A Study on the Efficacy and safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
2. Study Objectives:
Primary Objective: To evaluate the safety of CD19/CD20 CAR/TRuC-T cell therapy in patients with relapsed/refractory B-cell lymphoma.
Secondary Objective: To evaluate the efficacy of CD19/CD20 CAR/TRuC-T cell therapy in patients with relapsed/refractory B-cell lymphoma.
Exploratory Objective: To assess in vivo expansion and persistence of infused CD19/CD20 CAR/TRuC-T cells.
3. Participant Intervention:
Participants will receive lymphodepleting chemotherapy (FC regimen: Fludarabine + Cyclophosphamide) on Days -5, -4, and -3 relative to the planned CD19/CD20 CAR/TRuC-T cell infusion. The CAR/TRuC-T cell infusion will be administered 72 hours after the completion of the FC chemotherapy.

Start Date01 Jan 2025

Sponsor / Collaborator

Shenzhen University General Hospital

NCT04723914

/ Unknown statusPhase 1/2IIT

Clinical Trial of CD19/CD20 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Lymphoma

Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma .

Start Date20 Oct 2020

Sponsor / Collaborator

Shenzhen University General Hospital

100 Clinical Results associated with CD19/CD20 dual-target CAR-T (Shenzhen Universtiy)

Login to view more data

100 Translational Medicine associated with CD19/CD20 dual-target CAR-T (Shenzhen Universtiy)

Login to view more data

100 Patents (Medical) associated with CD19/CD20 dual-target CAR-T (Shenzhen Universtiy)

Login to view more data

100 Deals associated with CD19/CD20 dual-target CAR-T (Shenzhen Universtiy)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-cell lymphoma recurrent	Phase 2	China	Shenzhen University General Hospital	01 Oct 2023
B-cell lymphoma refractory	Phase 2	China	Shenzhen University General Hospital	01 Oct 2023
Carney Complex	Phase 2	China	Shenzhen University General Hospital	20 Oct 2020
Refractory Lymphoma	Phase 2	China	Shenzhen University General Hospital	20 Oct 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04723914 (Pubmed \| NEWS) Manual	Phase 1/2	B-Cell Lymphoma	11	CD19/CD20 dual-target CAR-T (Shenzhen Universtiy)	virzsjljhx(jpetluhxds) = qcorokfgen knzuroeuij (xgpsuahuid ) View more	Positive	07 Aug 2024